Article
Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Atherosclerosis - 1 Aug 1993
Cheung M C, Austin M A, Moulin P, Wolf A C, Cryer D, Knopp R H
Abstract excerpt
UNLABELLED: The HMG-CoA reductase inhibitor class of cholesterol-lowering agents reduces very low density lipoproteins (VLDL) and low density lipoproteins (LDL) and slightly increases high density lipoproteins (HDL). However, the effects of these agents on subclasses within the LDL and HDL fractions are not well understood. We have employed an HMG-CoA reductase inhibitor, pravastatin, to determine if LDL subclass...
Topics
- Adult
- Aged
- Apolipoproteins
- Carrier Proteins
- Cholesterol Ester Transfer Proteins
- Cholesterol Esters
- Female
- Glycoproteins
- Humans
- Hypercholesterolemia
- Lipids